The Enterprise Value as of September 2024 (TTM) for Morphic Holding, Inc. (MORF) is 2.81B

According to Morphic Holding, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.81B. This represents a change of 99.92% compared to the average of 1.41B of the last 4 quarters.

Morphic Holding, Inc. (MORF) Historical Enterprise Value (quarterly & annually)

How has MORF Enterprise Value performed in the past?

The mean historical Enterprise Value of Morphic Holding, Inc. over the last ten years is 770.99M. The current 2.81B Enterprise Value has changed 36.41% with respect to the historical average. Over the past ten years (40 quarters), MORF's Enterprise Value was at its highest in in the June 2023 quarter at 2.22B. The Enterprise Value was at its lowest in in the June 2018 quarter at 0.

Morphic Holding, Inc. (MORF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Morphic Holding, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Morphic Holding, Inc. (MORF) Average Enterprise Value

How has MORF Enterprise Value performed in the past?

The current Enterprise Value of Morphic Holding, Inc. (MORF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Morphic Holding, Inc. (MORF) Enterprise Value vs. Peers

How is MORF’s Enterprise Value compared to its peers?

Morphic Holding, Inc.’s Enterprise Value is less than Arcellx, Inc. (4.10B), greater than Ventyx Biosciences, Inc. (131.47M), greater than Immunocore Holdings plc (1.61B), less than Vaxcyte, Inc. (13.42B), greater than DICE Therapeutics, Inc. (2.21B), less than 89bio, Inc. (0), greater than Madrigal Pharmaceuticals, Inc. (696.30M), less than Pliant Therapeutics, Inc. (4.67B), greater than Stoke Therapeutics, Inc. (700.94M), greater than Akero Therapeutics, Inc. (588.57M), greater than Terns Pharmaceuticals, Inc. (1.61B), greater than Inozyme Pharma, Inc. (575.17M), greater than Viking Therapeutics, Inc. (408.51M), less than Revolution Medicines, Inc. (7.42B), less than Avidity Biosciences, Inc. (7.19B), less than Protagonist Therapeutics, Inc. (4.32B), greater than null (2.39B),

Build a custom stock screener for Morphic Holding, Inc. (MORF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Morphic Holding, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Morphic Holding, Inc. (MORF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Morphic Holding, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.